Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.

Arrieta AC, Sung L, Bradley JS, Zwaan CM, Gates D, Waskin H, Carmelitano P, Groll AH, Lehrnbecher T, Mangin E, Joshi A, Kartsonis NA, Walsh TJ, Paschke A.

PLoS One. 2019 Mar 26;14(3):e0212837. doi: 10.1371/journal.pone.0212837. eCollection 2019.

2.

A Population Pharmacokinetic Model for a Solid Oral Tablet Formulation of Posaconazole.

van Iersel MLPS, Rossenu S, de Greef R, Waskin H.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e02465-17. doi: 10.1128/AAC.02465-17. Print 2018 Jul.

3.

Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.

Cornely OA, Robertson MN, Haider S, Grigg A, Geddes M, Aoun M, Heinz WJ, Raad I, Schanz U, Meyer RG, Hammond SP, Mullane KM, Ostermann H, Ullmann AJ, Zimmerli S, Van Iersel MLPS, Hepler DA, Waskin H, Kartsonis NA, Maertens J.

J Antimicrob Chemother. 2017 Dec 1;72(12):3501. doi: 10.1093/jac/dkx382. No abstract available.

PMID:
29029280
4.

Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.

Cornely OA, Robertson MN, Haider S, Grigg A, Geddes M, Aoun M, Heinz WJ, Raad I, Schanz U, Meyer RG, Hammond SP, Mullane KM, Ostermann H, Ullmann AJ, Zimmerli S, Van Iersel MLPS, Hepler DA, Waskin H, Kartsonis NA, Maertens J.

J Antimicrob Chemother. 2017 Dec 1;72(12):3406-3413. doi: 10.1093/jac/dkx263. Erratum in: J Antimicrob Chemother. 2017 Dec 1;72(12):3501.

PMID:
28961714
5.

Effects of Treatment with Azoles Are Overstated.

Vendetti N, Salas M, Waskin H, Mast TC.

Am J Med. 2017 Aug;130(8):e367. doi: 10.1016/j.amjmed.2017.02.044. No abstract available.

PMID:
28734383
6.

Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.

Morillo CA, Waskin H, Sosa-Estani S, Del Carmen Bangher M, Cuneo C, Milesi R, Mallagray M, Apt W, Beloscar J, Gascon J, Molina I, Echeverria LE, Colombo H, Perez-Molina JA, Wyss F, Meeks B, Bonilla LR, Gao P, Wei B, McCarthy M, Yusuf S; STOP-CHAGAS Investigators.

J Am Coll Cardiol. 2017 Feb 28;69(8):939-947. doi: 10.1016/j.jacc.2016.12.023.

7.

Development of a PCR Assay to Detect Low Level Trypanosoma cruzi in Blood Specimens Collected with PAXgene Blood DNA Tubes for Clinical Trials Treating Chagas Disease.

Wei B, Chen L, Kibukawa M, Kang J, Waskin H, Marton M.

PLoS Negl Trop Dis. 2016 Dec 1;10(12):e0005146. doi: 10.1371/journal.pntd.0005146. eCollection 2016 Dec.

8.

Erratum for Kersemaekers et al., Pharmacokinetics and Safety Study of Posaconazole Intravenous Solution Administered Peripherally to Healthy Subjects.

Kersemaekers WM, van Iersel T, Nassander U, O'Mara E, Waskin H, Caceres M, van Iersel ML.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4426. doi: 10.1128/AAC.01001-16. Print 2016 Jul. No abstract available.

9.

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.

Cornely OA, Duarte RF, Haider S, Chandrasekar P, Helfgott D, Jiménez JL, Candoni A, Raad I, Laverdiere M, Langston A, Kartsonis N, Van Iersel M, Connelly N, Waskin H.

J Antimicrob Chemother. 2016 Jun;71(6):1747. doi: 10.1093/jac/dkw079. Epub 2016 Mar 8. No abstract available.

PMID:
26960721
10.

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.

Cornely OA, Duarte RF, Haider S, Chandrasekar P, Helfgott D, Jiménez JL, Candoni A, Raad I, Laverdiere M, Langston A, Kartsonis N, Van Iersel M, Connelly N, Waskin H.

J Antimicrob Chemother. 2016 Mar;71(3):718-26. doi: 10.1093/jac/dkv380. Epub 2015 Nov 26. Erratum in: J Antimicrob Chemother. 2016 Jun;71(6):1747.

PMID:
26612870
11.

Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation.

Kersemaekers WM, Dogterom P, Xu J, Marcantonio EE, de Greef R, Waskin H, van Iersel ML.

Antimicrob Agents Chemother. 2015;59(6):3385-9. doi: 10.1128/AAC.05000-14. Epub 2015 Mar 30.

12.

Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects.

Kersemaekers WM, van Iersel T, Nassander U, O'Mara E, Waskin H, Caceres M, van Iersel ML.

Antimicrob Agents Chemother. 2015 Feb;59(2):1246-51. doi: 10.1128/AAC.04223-14. Epub 2014 Dec 15. Erratum in: Antimicrob Agents Chemother. 2016 Jul;60(7):4426.

13.

Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.

Duarte RF, López-Jiménez J, Cornely OA, Laverdiere M, Helfgott D, Haider S, Chandrasekar P, Langston A, Perfect J, Ma L, van Iersel ML, Connelly N, Kartsonis N, Waskin H.

Antimicrob Agents Chemother. 2014 Oct;58(10):5758-65. doi: 10.1128/AAC.03050-14. Epub 2014 Jul 21.

14.

Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.

Kraft WK, Chang PS, van Iersel ML, Waskin H, Krishna G, Kersemaekers WM.

Antimicrob Agents Chemother. 2014 Jul;58(7):4020-5. doi: 10.1128/AAC.02448-13. Epub 2014 May 5.

15.

Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.

Maertens J, Cornely OA, Ullmann AJ, Heinz WJ, Krishna G, Patino H, Caceres M, Kartsonis N, Waskin H, Robertson MN.

Antimicrob Agents Chemother. 2014 Jul;58(7):3610-7. doi: 10.1128/AAC.02686-13. Epub 2014 Apr 14.

17.

Amphotericin B lipid complex for neonatal invasive candidiasis.

Adler-Shohet F, Waskin H, Lieberman JM.

Arch Dis Child Fetal Neonatal Ed. 2001 Mar;84(2):F131-3.

18.

Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET).

Heald AE, Hoffman JM, Bartlett JA, Waskin HA.

Int J STD AIDS. 1996 Aug-Sep;7(5):337-46.

PMID:
8894823
19.

Zygomycosis (mucormycosis) and HIV infection: report of three cases and review.

Nagy-Agren SE, Chu P, Smith GJ, Waskin HA, Altice FL.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 1;10(4):441-9. Review.

PMID:
7583440
20.

A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.

Powderly WG, Finkelstein D, Feinberg J, Frame P, He W, van der Horst C, Koletar SL, Eyster ME, Carey J, Waskin H, et al.

N Engl J Med. 1995 Mar 16;332(11):700-5.

21.
22.

Differences between men and women with HIV-related Pneumocystis carinii pneumonia: experience from 3,070 cases in New York City in 1987.

Bastian L, Bennett CL, Adams J, Waskin H, Divine G, Edlin BR.

J Acquir Immune Defic Syndr. 1993 Jun;6(6):617-23.

PMID:
8496791
23.

FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS.

Hoffman JM, Waskin HA, Schifter T, Hanson MW, Gray L, Rosenfeld S, Coleman RE.

J Nucl Med. 1993 Apr;34(4):567-75.

24.
25.

Syphilitic cerebral gumma with HIV infection.

Berger JR, Waskin H, Pall L, Hensley G, Ihmedian I, Post MJ.

Neurology. 1992 Jul;42(7):1282-7.

PMID:
1620334
26.

Prevalence of antibody to Trypanosoma cruzi among blood donors in Los Angeles, California.

Kerndt PR, Waskin HA, Kirchhoff LV, Steurer F, Waterman SH, Nelson JM, Gellert GA, Shulman IA.

Transfusion. 1991 Nov-Dec;31(9):814-8.

PMID:
1755086
27.

Aerosol pentamidine prophylaxis following Pneumocystis carinii pneumonia in AIDS patients: results of a blinded dose-comparison study using an ultrasonic nebulizer.

Murphy RL, Lavelle JP, Allan JD, Gordin FM, Dupliss R, Boswell SL, Waskin HA, Davies SF, Graziano FM, Saag MS, et al.

Am J Med. 1991 Apr;90(4):418-26.

PMID:
2012082
28.

Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome.

Cameron ML, Bartlett JA, Gallis HA, Waskin HA.

Rev Infect Dis. 1991 Jan-Feb;13(1):64-7.

PMID:
2017634
29.

Treatment of systemic sporotrichosis with ketoconazole.

Calhoun DL, Waskin H, White MP, Bonner JR, Mulholland JH, Rumans LW, Stevens DA, Galgiani JN.

Rev Infect Dis. 1991 Jan-Feb;13(1):47-51.

PMID:
2017630
30.

Occupational exposure to aerosolized pentamidine.

Montgomery AB, Corkery KJ, Brunette ER, Leoung GS, Waskin H, Debs RJ.

Chest. 1990 Aug;98(2):386-8.

PMID:
2376170
31.

Cryptococcal disease in AIDS.

Bozzette SA, Waskin HA.

AIDS Clin Rev. 1990:193-213. Review. No abstract available.

PMID:
2083177
32.

Severe African trypanosomiasis with spurious hypoglycemia.

Nieman RE, Kelly JJ, Waskin HA.

J Infect Dis. 1989 Feb;159(2):360-2. No abstract available.

PMID:
2915160
33.

Risk factors for hypoglycemia associated with pentamidine therapy for Pneumocystis pneumonia.

Waskin H, Stehr-Green JK, Helmick CG, Sattler FR.

JAMA. 1988 Jul 15;260(3):345-7.

PMID:
3259989
34.

Giardia transmission in a swimming pool.

Porter JD, Ragazzoni HP, Buchanon JD, Waskin HA, Juranek DD, Parkin WE.

Am J Public Health. 1988 Jun;78(6):659-62.

35.

Epidemic giardiasis caused by a contaminated public water supply.

Kent GP, Greenspan JR, Herndon JL, Mofenson LM, Harris JA, Eng TR, Waskin HA.

Am J Public Health. 1988 Feb;78(2):139-43.

36.

Pentamidine and fatal hypoglycemia.

Sattler FR, Waskin H.

Ann Intern Med. 1987 Nov;107(5):789-90. No abstract available.

PMID:
3662308
37.

Persistence of high-risk sexual activity among homosexual men in an area of low incidence of the acquired immunodeficiency syndrome.

Jones CC, Waskin H, Gerety B, Skipper BJ, Hull HF, Mertz GJ.

Sex Transm Dis. 1987 Apr-Jun;14(2):79-82.

PMID:
3649962
38.

Prevalence of HTLV-III antibody among New Mexico residents with hemophilia.

Waskin H, Smith KJ, Simon TL, Gribble TJ, Mertz GJ.

West J Med. 1986 Oct;145(4):477-80.

39.

Prevention of clindamycin-induced colitis in hamsters by Clostridium sordellii antitoxin.

Allo M, Silva J Jr, Fekety R, Rifkin GD, Waskin H.

Gastroenterology. 1979 Feb;76(2):351-5.

PMID:
759263

Supplemental Content

Loading ...
Support Center